4//SEC Filing
Topper David Joseph 4
Accession 0000899243-22-036936
CIK 0001828326other
Filed
Nov 22, 7:00 PM ET
Accepted
Nov 23, 4:31 PM ET
Size
5.8 KB
Accession
0000899243-22-036936
Insider Transaction Report
Form 4
Topper David Joseph
DirectorChief Financial Officer
Transactions
- Exercise/Conversion
Class B Ordinary Shares
2022-11-22−30,000→ 0 total→ Class A Ordinary Shares (30,000 underlying)
Footnotes (1)
- [F1]Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022.
Documents
Issuer
Frazier Lifesciences Acquisition Corp
CIK 0001828326
Entity typeother
Related Parties
1- filerCIK 0001740378
Filing Metadata
- Form type
- 4
- Filed
- Nov 22, 7:00 PM ET
- Accepted
- Nov 23, 4:31 PM ET
- Size
- 5.8 KB